Evaluation of neoadjuvant chemotherapeutic response of breast cancer using dynamic MRI with high temporal resolution

European Radiology

Volumn 13, Issue 1, 2003, Pages 80-87

  Wasser, Klaus ^a   Klein, S K ^a   Fink, C ^a   Junkermann, H ^b   Sinn, H P ^c   Zuna, I ^a   Knopp, M V ^d   Delorme, S ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b Zentralkrankenhaus   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d OHIO STATE UNIVERSITY   (United States)

Author keywords

Breast neoplasms; Chemotherapy; Follow up studies; MRI

Indexed keywords

EPIRUBICIN; GADOLINIUM PENTETATE; NUCLEAR MAGNETIC RESONANCE IMAGING AGENT; PACLITAXEL; ANTINEOPLASTIC AGENT;

ADVANCED CANCER; ARTICLE; BREAST CANCER; BREAST TUMOR; CANCER STAGING; CLINICAL ARTICLE; COMPARTMENT MODEL; CONTRAST ENHANCEMENT; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG DISTRIBUTION; DRUG EFFECT; DRUG ELIMINATION; DRUG RESPONSE; FEMALE; HISTOPATHOLOGY; HUMAN; IMAGE ANALYSIS; MAMMOGRAPHY; MASTECTOMY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RADIOLOGICAL PARAMETERS; TUMOR REGRESSION; TUMOR VOLUME; ADJUVANT THERAPY; IMAGE PROCESSING; MIDDLE AGED;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; NEOADJUVANT THERAPY;

EID: 0038321023     PISSN: 09387994     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00330-002-1654-1     Document Type: Article

References (31)

1. Hortobagyi GN, Ames FC, Buzdar AU, Kau SW, McNeese MD, Paulus D, Hug V, Holmes FA, Romsdahl MM, Fraschini G (1988) Management of stage III primary breast cancer with primary chemotherapy, surgery, and radiation therapy. Cancer 62:2507-2516
2. Swain SM, Sorace RA, Bagley CS, Danforth DN Jr, Bader J, Wesley MN, Steinberg SM, Lippman ME (1987) Neoadjuvant chemotherapy in the combined modality approach of locally advanced nonmetastatic breast cancer. Cancer Res 47:3889-3894
3. Singletary SE, McNeese MD, Hortobagyi GN (1992) Feasibility of breast-conservation surgery after induction chemotherapy for locally advanced breast carcinoma. Cancer 69:2849-2852
4. Bonadonna G, Veronesi U, Brambilla C, Ferrari L, Luini A, Greco M, Bartoli C, Coopmans de Yoldi G, Zucali R, Rilke F (1990) Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more. J Natl Cancer Inst 82:1539-1545
5. Mauriac L, Durand M, Avril A, Dilhuydy JM (1991) Effects of primary chemotherapy in conservative treatment of breast cancer patients with operable tumors larger than 3 cm. Results of a randomized trial in a single centre. Ann Oncol 2:347-354
6. Schwartz GF, Birchansky CA, Komarnicky LT, Mansfield CM, Cantor RI, Biermann WA, Fellin FM, McFarlane J (1994) Induction chemotherapy followed by breast conservation for locally advanced carcinoma of the breast. Cancer 73:362-369
7. Abraham DC, Jones RC, Jones SE, Cheek JH, Peters GN, Knox SM, Grant MD, Hampe DW, Savino DA, Harms SE (1996) Evaluation of neoadjuvant chemotherapeutic response of locally advanced breast cancer by magnetic resonance imaging. Cancer 78:91-100
8. Weatherall PT, Evans GF, Metzger GJ, Saborrian MH, Leitch AM (2001) MRI vs histologic measurement of breast cancer following chemotherapy: comparison with X-ray mammography and palpation. J Magn Reson Imaging 13:868-875
9. Cocconi G, Blasio B di, Alberti G, Bisagni G, Botti E, Peracchia G (1984) Problems in evaluating response of primary breast cancer to systemic therapy. Breast Cancer Res Treat 4:309-313
10. Huber S, Wagner M, Zuna I, Medl M, Czembirek H, Delorme S (2000) Locally advanced breast carcinoma: evaluation of mammography in the prediction of residual disease after induction chemotherapy. Anticancer Res 20:553-558
11. Vinnicombe SJ, MacVicar AD, Guy RL, Sloane JP, Powles TJ, Knee G, Husband JE (1996) Primary breast cancer: mammographic changes after neoadjuvant chemotherapy, with pathologic correlation. Radiology 198:333-340
12. Gilles R, Guinebretiere JM, Toussaint C, Spielman M, Rietjens M, Petit JY, Contesso G, Masselot J, Vanel D (1994) Locally advanced breast cancer: contrast-enhanced subtraction MR imaging of response to preoperative chemotherapy. Radiology 191:633-638
13. Knopp MV, Brix G, Junkermann HJ, Sinn HP (1994) MR mammography with pharmacokinetic mapping for monitoring of breast cancer treatment during neoadjuvant therapy. Magn Reson Imaging Clin N Am 2:633-658
14. Rieber A, Zeitler H, Rosenthal H, Gorich J, Kreienberg R, Brambs HJ, Tomczak R (1997) MRI of breast cancer: influence of chemotherapy on sensitivity. Br J Radiol 70:452-458
15. Rieber A, Brambs HJ, Gabelmann A, Heilmann V, Kreienberg R, Kühn T (2002) Breast MRI for monitoring response of primary breast cancer to neoadjuvant chemotherapy. Eur Radiol 12:1711-1719
16. Tofts PS, Brix G, Buckley DL, Evelhoch JL, Henderson E, Knopp MV, Larsson HB, Lee TY, Mayr NA, Parker GJ, Port RE, Taylor J, Weisskoff RM (1999) Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging 10:223-232
17. Brix G, Schreiber W, Hoffmann U, Gückel F, Hawighorst H, Knopp MV (1997) Methodical approaches to quantitative evaluation of microcirculation in tissues with dynamic magnetic resonance tomography. Radiologe 37:470-480
18. Hawighorst H, Weikel W, Knapstein PG, Knopp MV, Zuna I, Schönberg SO, Vaupel P, van Kaick G (1998) Angiogenetic activity of cervical carcinoma: assessment by functional magnetic resonance imaging-based parameters and a histomorphological approach in correlation with disease outcome. Clin Cancer Res 4:2305-2312
19. Müller-Schimpfle M, Brix G, Layer G, Schlag P, Engenhart R, Frohmuller S, Hess T, Zuna I, Semmler W, van Kaick G (1993) Recurrent rectal cancer: diagnosis with dynamic MR imaging. Radiology 189:881-889
20. Hess T, Knopp MV, Hoffmann U, Brix G, Junkermann H, Zuna I, Fournier D von van Kaick G (1994) A pharmacokinetic analysis of Gd-DTPA enhancement in MRT in breast carcinoma. Fortschr Röntgenstr 6:518-523
21. Wasser K, Delorme S, Moehler T, Neben K, Zuna I, Goldschmidt H, van Kaick G (2001) Contrast enhanced dynamic MRI in patients with multiple myeloma and diffuse bone marrow vertebral infiltration during thalidomide therapy or combined thalidomide and chemotherapy. Eur Radiol 11 (Suppl 1):262
22. Wasser K, Delorme S, van Kaick G (2001) Radiologische Diagnostik kleinster Gefäse - die nicht-invasive Untersuchung der Mikrozirkulation von neoplastischen Erkrankungen. Onkologe 7:1134-1144
23. Knopp MV, Weiss E, Sinn HP, Mattern J, Junkermann H, Radeleff J, Magener A, Brix G, Delorme S, Zuna I, van Kaick G (1999) Pathophysiologic basis of contrast enhancement in breast tumors. J Magn Reson Imaging 10:260-266
24. Knopp MV, Obier C, Zuna I, Junkermann H, Hess T, Junkermann I, Brix G, van Kaick G (1998) Multi-reader-analysis to assess functional MR-mammography. Radiologe 38:307-314
25. Hoffmann U, Brix G, Knopp MV, Hess T, Lorenz WJ (1995) Pharmacokinetic mapping of the breast: a new method for dynamic MR mammography. Magn Reson Med 33:506-514
26. Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47:207-214
27. Sinn HP, Schmid H, Junkermann H, Huober J, Leppien G, Kaufmann M, Bastert G, Otto HF (1994) Histologic regression of breast cancer after primary (neoadjuvant) chemotherapy. Geburtshilfe Frauenheilkd 54:552-558
28. Wasser K, Fink C, Junkermann H, Lüdemann HP, Sinn HP, Zuna S, Delorme S (2002) Histological regression of breast tumours after neoadjuvant chemotherapy: influence on the preoperative MRI tumour measurement. Eur Radiol 12 (Suppl 1):158
29. Davis PL, Staiger MJ, Harris KB, Gannott MA, Klementaviciene J, McCarty KS, Trobon H (1996) Breast cancer measurements with magnetic resonance imaging, ultrasonography and mammography. Breast Cancer Res Treat 37:1-9
30. Mumtaz H, Hall-Craggs MA, Davidson T, Walmsley K, Thurell W, Kissin MW, Taylor I (1997) Staging of symptomatic primary breast cancer with MR imaging. Am J Roentgenol 169:417-424
31. Gasparini G (2001) Metronomic scheduling: the future of chemotherapy? Lancet Oncol 2:733-740